Jon Stonehouse

Track

Insider profile

Currently holds positions in Bellicum Pharmaceuticals Inc and BioCryst Pharmaceuticals, Inc.

Performance

Overall performance
3.3
Performance over holding periods
3.3
30 days 90 days 120 days
Average return 14% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
1 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Bellicum Pharmaceuticals Inc Dec. 5, 2014 -
President, Chief Executive Officer, Director BioCryst Pharmaceuticals, Inc. July 13, 2007 -
Jon Stonehouse's trades of BioCryst Pharmaceuticals, Inc.'s stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-02 2026-03-02
PrS Proposed sale
36,986
349.55
US$1,896,238 		36,986 349.55 US$1,896,238
2024-05-15 2024-05-13
B Purchase
28,729 -46.3%
12.63
US$1,174,651 		28,729 -46.3% 12.63 US$1,174,651
2023-02-02 2023-02-01
PlS Planned sale
5,098 -18.6%
91.21
US$1,844,319 		5,098 -18.6% 91.21 US$1,844,319
2022-12-19 2022-12-15
PlS Planned sale
14,100 -1.6%
10.90
US$153,690 		14,100 -1.6% 10.90 US$153,690
2022-12-02 2022-12-02
PlS Planned sale
82,656 -8.4%
12.80
US$1,057,997 		82,656 -8.4% 12.80 US$1,057,997
2022-12-02 2022-12-01
PlS Planned sale
214,917 -19.2%
13.00
US$2,793,921 		214,917 -19.2% 13.00 US$2,793,921
2022-01-13 2022-01-11
PlS Planned sale
184,000 -16.9%
15.04
US$2,767,360 		184,000 -16.9% 15.04 US$2,767,360
2020-12-17 2020-12-15
PlS Planned sale
134,278 -14.6%
8.32
US$1,117,193 		134,278 -14.6% 8.32 US$1,117,193